Gland Pharma Limited received approval from the FDA for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill). Gland Pharma said the product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan, latanoprost ophthalmic solution 0.005% (50 μg/mL) held by UPJOHN US 2 LLC.

This medication is used for the treatment of high IOP in patients with open-angle glaucoma or ocular hypertension, the company said in a press release. 

Gland Pharma said it expects to launch this product through its marketing partners in FY25.